BRINGING TRANSFORMATIONAL THERAPY TO PATIENTS
– Creating Value Through Innovation

Villanova University, Connelly Conference Center
800 Lancaster Avenue, Villanova, PA 19085
June 19-20, 2015
Greetings from Conference Co-Chairs

Dear SAPA-GP Members and Friends:

Welcome to the 2015 SAPA-GP Annual Conference! We are excited to have you here!

The Conference Organizing Committee has put together a fabulous program with a theme of “Bringing Transformational Therapy to Patients – Creating Value Through Innovation”. The global biopharmaceutical industry is going through a transformation, striving to increase R&D productivity, reduce costs, and develop drugs/vaccines that address unmet medical needs. Recent developments in the fields such as Immune-oncology and Hepatitis C are great examples. SAPA-GP is a dedicated professional organization determined to play an active role in bringing innovative medicines to patients worldwide.

This year’s conference consists of four sessions, each focusing on one particular aspect of innovative drug R&D:

- New Era of Breakthrough Science and Therapeutics
- Global Partnerships to Maximize Patient Benefit
- Global Success in Commercialization of Innovative Therapies – a Joint Session with BayHelix
- Product Development in a Changing Regulatory and Healthcare Environment

Prominent scientists, senior executives, and policy makers from both America and China will share their ideas and insights on these important topics. We know you will enjoy the conference!

In retrospect, 2014/2015 has been another banner year for SAPA-GP.

**Continuing to Build the SAPA-GP Strategic Platform**

We have grown stronger with global strategic influencer in the biopharmaceutical industry. We continued to build our valuable SAPA-GP platform, leveraging its
unique status as the professional organization that links two largest pharmaceutical markets, US and China, to build awareness and create value.

In September of 2014, SAPA-GP entered into a strategic alliance with China Tianjin BinHai Anti-Cancer Drug Development Industry Union. The alliance is the third of its kind for SAPA-GP. Both parties intend to achieve broader reach and impact through collaboration. In October, SAPA-GP co-organized the 12th China International Pharmaceutical Advanced Technology Commercial Development and Partnering Summit in Beijing. More recently, in May 2015, SAPA-GP co-organized Global Vaccine and Antibody China Summit 2015 in Shanghai, China.

We are excited to join forces with Rockland Immunochemicals Inc. in 2015 to establish the Joy Cappel Young Investigators Award for young talents in life sciences. This prestigious award underscores our shared passion for life sciences and developing the talent of the next generation.

SAPA-GP’s status as a leading global force is best shown at our annual conferences. Two important delegations will join this year’s annual conference, Chengdu Municipal Government Delegation and China Pharmaceutical Enterprises Association (CPEA). Chengdu is a booming metropolitan city on a spirited journey to build biotechnology as one of its pillar industries. CPEA is China’s premium national coalition of pharmaceutical companies. SAPA-GP is excited to have the opportunity to host both delegations and looks forward to future collaborations.

Serving Members and the Professional Community

SAPA-GP owes its livelihood to the members. We exist because we serve. SAPA-GP takes a customer centric strategy in shaping our member engagement model, focusing our energy where our members care the most and need the most.

Promoting scientific excellence and technical learning has been the core mission of ours. In the last year, we organized six webinar lectures with wide-ranging topics covering drug metabolism, industry overview, business development,
portfolio management, and venture investment. The webinar series was
designed to focus on both cutting edge science and business value creation.
Compared to previous ones, these lectures covered new and exciting topics not
only in basic pharmaceutical sciences but also in business and finance. With
over four hundred participants from all over the world, our webinar series has
become a flagship product of SAPA-GP.

Promoting member career growth is another anchoring mission of SAPA-GP.
Our members are always on the lookout for effective ways to expand network, to
identify opportunities and to grow career. We have organized two career
development workshops in 2014: one for graduating students and the other for
experienced professionals.

We have identified a group of students from local universities to organize the
student Career Development Workshop. They did a fantastic job! From the
beginning to the end, the workshop was designed by students and for students,
all the while leveraging the rich resources afforded by SAPA-GP. More than 200
students from the states of Pennsylvania, New Jersey, Delaware and New York
attended the exciting event on the historical University of Pennsylvania campus.
For the professional workshop, we tapped into industrial leaders and professional
recruiters to share experiences and inspire systematic career planning. Among
many distinguished speakers, we invited Wharton School Professor Stewart
Friedman, whose book “Leading the Life You Want” was one of Wall Street
Journal Bestsellers. The opportunity to interact with Prof. Friedman, one of the
best career coaches in the world, and many others greatly enhanced the
experience of workshop participants.

We are proud to be the platform of choice for our members to launch and
manage their careers in the ever changing healthcare industry.

**Operational Improvement and Sustainability**

An organization is only as strong as its leaders. SAPA-GP Senior Leadership
Team has a strategic focus on recruiting and developing future leaders. We are
extremely happy to see many new faces in the Working Group. Young SAPA-GP
leaders stepped up to organize career development workshops, webinar series, picnic for friends and families, and many other activities throughout the year. These young leaders will serve SAPA-GP well for years to come.

In the past year, new measures were introduced to improve operation efficiency and ultimately to secure long term sustainability. Under the leadership of SAPA-GP treasurer, we constructed a comprehensive annual budget at the beginning of the year. The process fostered great discussions about the year’s plan and helped us to focus limited resources on the most important tasks. Financial management rigor is not only a compliance concept but also a cornerstone for sustainability.

In early 2015, SAPA-GP and Morgan Stanley Wealth Management entered into an asset management agreement, leveraging MS’s knowhow and advantageous fee structure for nonprofit organizations to safeguard our limited asset base against inflationary risk, thus improve our ability to fulfill fiduciary duty on behalf of our members and industrial partners.

SAPA-GP leadership team worked tirelessly to strengthen the financial foundation in order to enable long term growth. The tremendous efforts successfully broadened the pool of business partners and resulted in another solid year in fundraising.

SAPA-GP has been growing successfully for over twelve years. We are grateful for the opportunity to serve our members but never take the privilege for granted. We know that we cannot do what we do without the broad support from partners. We constantly look for new ways to strengthen our relationship based on a win-win proposition. We believe only mutually beneficial relationship can be sustained and we are fully committed to building and expanding collaboration with our industrial partners in the future.

As we reflect on the achievements in the past year, we want to thank our Working Group, Executive Committee and Senior Leadership Team members, who put their hands together to make everything happen. We are very grateful to have the strong support by previous SAPA-GP leaders, friends and supporters.
They made our jobs much easier and much more impactful. Finally many thanks to our families, who have been patiently supporting our volunteering services. We thank their understanding when we are absent from many important family activities.

The past year has been a short but great journey. We are more confident than ever that SAPA-GP is well on its way to becoming an even greater organization, and we count on your continued support.

Once again, welcome to SAPA-GP 2015 Annual Conference!

Xi-Yong (Sean) Fu, PhD, MBA
Conference Co-Chair
SAPA-GP President
Finance Director, Merck & Co.

Aston Liu, PhD
Conference Co-Chair
SAPA-GP President-Elect
Director, Biopharm CMC, GlaxoSmithKline
US-China BioPharm Congress
Philadelphia 2015
SAPA-GP
13th Annual Conference

Organizing Committee

Co-Chairs: Xi-Yong (Sean) Fu, Aston Liu
Members:
Kevin Bai      David Cragin      Li Cui      Weiguo Dai      Patrick Deng
Lili Guo       Yingke He         Laura Hong    Tianjing Hu     Mabel Ju
Jiangfan Li    Xue Liang         Yin Liang     Weiyi Liu        Allen Luo
Yangsi Ou      Fang Shen         Bin Shi       Ping Song       Yongchao Su
Hao Sun        Hui Wang           Kun Wang      Xizhuo Wang     Hao Wu
Shuang Wu      Zhenhua Wu        Yan Xu        Jing Yang       Mike Yu
Jennifer Yuan  Aming Zhang       Jingyi Zhang  Sean Zhang     Yuemei Zhang

Editor in Chief: Bin Shi, Jing Yang
Art Design: Lili Guo, Shuang Wu
Brochure Editing: Li Cui, Tianjing Hu, Xizhuo Wang and Hao Wu

SAPA-GP Advisory Committee
Chair: Weiguo Dai (President 2013-2014)

Sean Zhang (President 2012-2013)       Jian Li (President 2006-2007)
Laura Hong (President 2011-2012)       Li Shi (President 2005-2006)
Jingsong Wang (President 2010-2011)    HanCheng Zhang (President 2004-2005)
Tsang-Bin Tzeng (President 2009-2010)  Bo Liang (President 2003-2004)
Li Yan (President 2008-2009)           De-Min Zhu (Treasurer)
Zhongda Zhang (President 2007-2008)

SAPA-GP Scientific Advisory Committee

RuiPing Dong, MD, PhD      Managing Director, Ruiping Consulting
Evan Loh, MD               President & CMO, Paratek Pharmaceuticals
David Shen, PhD            Vice President, NGM Biopharmaceuticals
Steven Yang, PhD           COO, WuXi AppTec
Zhenping Zhu, MD, PhD      Executive VP, Kadmon, President and CEO, Kadmon China
**SAPA’s History**

The Sino-American Pharmaceutical Professionals Association (SAPA) was founded in 1993 as a non-profit organization. SAPA has grown rapidly and has become one of the most active and well recognized professional organizations in the United States. SAPA’s membership base now stands at approximately 4,000 scientists and researchers in the United States.

The Greater Philadelphia (GP) area is one of the major homes for the world pharmaceutical industry. It hosts more than half of the world’s top-ten pharmaceutical companies, and many mid/small pharmaceutical/biotech companies as well as academic institutions. SAPA-GP was established in 2002 to serve the rapidly growing pharmaceutical/biotech/healthcare community in the GP area.

**SAPA-GP’s Mission**

To serve its membership, the pharmaceutical sciences, the biomedical and biotechnological community, the health professions, and the interest of the public health by:

- Promoting all aspects of the pharmaceutical and biopharmaceutical sciences, including both academic as well as industrial interests and providing for recognition of individual achievement;
- Fostering education, career growth and the personal development of its members;
- Providing a forum for open interchange and dissemination of scientific knowledge;
- Bridging and developing the relationship in the pharmaceutical area between US and China.

- 09/18/2014 SAPA-GP made strategic alliance with Tianjin Binhai Anti-Cancer Drug Development Industry Union in Tianjin, China
- 10/26/2014 SAPA-GP Career Development Workshop for Students at University of Pennsylvania, Philadelphia, PA, USA
- 10/28/2014 SAPA-GP co-organized the 12th China International Pharmaceutical Advanced Technology Commercial Development and Partnering Summit in Beijing, China
- 12/06/2014 SAPA-GP Career Development Workshop for Professionals, Holliday Inn, Fort Washington, PA, USA
- 03/07/2015 SAPA-GP co-organized UDCA 2015 Lunar New Year Music Gala at Upper Dublin High School Performing Arts Center, Fort Washington, PA, USA
- 05/07/2015 SAPA-GP co-organized Global Vaccine and Antibody China Summit 2015 in Shanghai, China
- 05/10/2015 SAPA-GP Annual Picnic at Peace Valley Park, Doylestown, PA, USA

Webinars
- 10/02/2014 Introduction to Drug Metabolism: Case Studies for Its Impacts on Drug Discovery and Development by Zhoupeng Zhang, PhD, Merck Research Laboratories
- 11/20/2014 Create Value Through Investing in Science - a Business Overview of the Biopharmaceutical Industry by Sean Fu, PhD, MBA, President, SAPA-GP, Finance Director, Merck

Webinar Miniseries: From Drug Innovation to Commercial Success
- 03/12/2015 Business Development as Strategic Growth Enabler: Licensing, Co-Promo, and M&A by Jie Liu, MBA, Senior Director, Global Corporate Development and Strategy, Teva Pharmaceuticals
- 04/09/2015 Ascertaining New Drug Potential in Crowded Therapeutic Market: Late Stage Portfolio Assessment Priorities by Albert Ren, PhD, Director of Global Clinical Development Finance, Merck
- 04/29/2015 Healthcare Venture in the US: the Mechanics, the Players, and the Playing Fields by Ming Fang, MBA, Principal, Safeguard Scientifcs
- 05/13/2015 Turn Innovation into Real Growth: New Drug Launch and In-Line Marketing by Kai Li, PhD, MBA, Brand Director, Zytiga®, Johnson & Johnson
Conference Agenda

Friday, June 19, 2015

1:00 – 1:30 PM
Check-in and Networking

1:30 – 1:40 PM
Opening Remarks
Xi-Yong (Sean) Fu, PhD, MBA
President, SAPA-GP; Finance Director, R&D, Merck & Co., Inc.

1:40 – 1:55 PM
Introducing SAPA-GP Presidential Candidates and Q&A
Aston Liu, PhD
President-Elect, SAPA-GP; Director, Biopharm CMC, GlaxoSmithKline

Session I: New Era of Breakthrough Science and Therapeutics

1:55 – 4:35 PM

Moderators:
Fang Shen, PhD
Principal Scientist, Immunology Discovery, Johnson and Johnson
Yingke He, MBA, MS
Portfolio Lead, BioMPD, GlaxoSmithKline

1:55 – 2:30 PM
Keynote Address
Innovation: Biology and Engineering to Deliver Innovations in Medicine
Michael Thien, ScD
Senior Vice President, Science and Technology Commercialization, Merck & Co., Inc.

2:30 – 2:55 PM
Engineering Immune Cells from Patients to Treat Their Untreatable Cancer
Bruce Levine, PhD
Director, Clinical Cell and Vaccine Production Facility, University of Pennsylvania

2:55 – 3:10 PM
Coffee Break
Moderators:
Bin Shi, PhD
Associate Principle Scientist, In Vivo Pharmacology, Merck & Co., Inc.
Aming Zhang, PhD
Investigator, Biopharm Analytical Sciences, GlaxoSmithKline

3:10 – 3:45 PM
Keynote Address
Science, Medicine and Brain – Perception and Reality
Min Li, PhD
Senior Vice President, Head of Neurosciences Therapy Area & Head of R&D China, GlaxoSmithKline

3:45 – 4:10 PM
The Ongoing Revolution in the Treatment of Hepatitis C
Eliav Barr, MD
Vice President, Head of Infectious Diseases Therapeutic Area, Global Clinical Development, Merck & Co., Inc.

4:10 – 4:35 PM
Vision and Ambition: How to Grow a Chinese Healthcare Company in the Local Pharma Environment
Yanping Zhao, MBA
CEO, Harbin Gloria Pharmaceuticals Co., Ltd.

Panel Discussion:
Delivering Life-Changing Therapies to Patients Worldwide

4:35 – 5:30 PM

Moderators:
Li Shi, PhD
CEO and Board Director, Shanghai Zerun Biotechnology Co., Ltd; Vice President, Walvax Corporate, Walvax Co., Ltd
Xizhuo (Cici) Wang
PhD candidate, Temple University

4:35 – 5:30 PM

Panelists:
Feng (Frank) Li, PhD
President and Co-Founder, Alliance Pharma, Inc.
Rong-Cheng Li
Partner, Beijing Kang Zhun Medical Technology Co.
Li Shi, PhD  
CEO and Board Director, Shanghai Zerun Biotechnology Co., Ltd.;  
Vice President, Walvax Corporate, Walvax Co., Ltd.

Zhongda Zhang, PhD  
Vice President, Business Development, Pharmaron

De-Min Zhu, PhD  
President & CEO, Cureport, Inc.

Cocktail Reception

大费城美中医药协会欢迎酒会

(Complimentary to All Registered Attendees and Speakers)

5:30 – 6:10 PM
Opening Night Gala
大费城美中医药协会 2015 年年会晚宴
成都金沙之夜
6:10 – 9:00 PM

Masters of Ceremony:
Mabel Ju, MS, MBA
Senior Financial Analyst, Financial Planning & Analysis, Merck & Co., Inc.
Fang Shen, PhD
Principal Scientist, Immunology Discovery, Johnson and Johnson

6:10 – 6:20 PM
Special Remarks
Dongbai Ye (叶冬柏)
Science and Technology Counselor, Consulate General of P. R. China in New York (中国驻纽约总领事馆科技参赞)

6:20 – 6:50 PM
Keynote Speech: Opportunities for Healthcare Industries in Chengdu
Chunlin Han, PhD
Assistant Mayor, City of Chengdu, China

6:50 – 7:00 PM
Joy Cappel 2015 Young Investigator Award
James Fendrick
CEO and President, Rockland Immunochemicals, Inc.

7:00 – 7:15 PM
SAPA-GP Year in Review & Awards Ceremony
Xi-Yong (Sean) Fu, PhD, MBA
President, SAPA-GP; Finance Director, R&D, Merck & Co., Inc.

7:15 – 7:25 PM
SAPA-GP Presidential Election
Aston Liu, PhD
President-Elect, SAPA-GP; Director, Biopharm CMC, GlaxoSmithKline

7:25 – 9:00 PM
Dinner
Music by DJ Mark Shepperd
“This new venture at Rockland is very exciting as it paves the way for future collaborations between leading research institutions and our own Rockland experts.”

800.656.7625  jcyia@rockland-inc.com  www.rockland-inc.com/young-investigators
Saturday, June 20, 2015

8:30 – 9:00 AM
Check-in and Networking

9:00 – 9:10 AM
Welcome Remarks
Xi-Yong (Sean) Fu, PhD, MBA
President, SAPA-GP; Finance Director, R&D, Merck & Co., Inc.

Session II: Global Partnerships to Maximize Patient Benefit

9:10 AM – 12:05 AM

Moderators:
Jing Yang, PhD
Senior Principal Scientist, Discovery Biology, Bristol-Myers Squibb
Kelvin Bai, PhD
Research Scientist II, Molecular and Analytical Development, Bristol-Myers Squibb

9:10 – 9:45 AM
Keynote Address
Repairing the Heart After Heart Attack
Steven R. Houser, PhD, FAHA
2016-2017 President-Elect of American Heart Association; Senior Associate Dean of Research, Director of Cardiovascular Research, Chair of Cardiovascular Research Center, Temple University

9:45 – 10:10 AM
Drive Genomics-Based Innovations in Immune Therapy and Antibody Discovery
Shifang Zhang, PhD
Vice President, Corporate development, GENEWIZ. LLC.

10:10 – 10:25 AM
Harnessing the Synergies of Singapore, Chengdu and the Rest of West China
Joon-Woon Chong
Vice President, Strategic Planning & Investment Promotion, Business Development & Commercial, Sembcorp Development

10:25 – 10:40 AM
Coffee Break
Moderators:
**Aston Liu, PhD**
President-Elect, SAPA-GP; Director, Biopharm CMC, GlaxoSmithKline
**Hao Sun, MS**
Chemist III, Frontage Laboratories, Inc.

10:40 – 11:15 AM
**Keynote Address**
**Collaboration, Convergence, Innovation Redefined**
**Edward Hu, MS, MBA**
Chief Financial Officer and Chief Investment Officer, WuXi AppTec Co., Inc.

11:15 – 11:40 AM
**Synthetic Biology - a Frontier of Biotechnology and Its Relevance to the Biomedical World**
**Jeffrey Hung, PhD, MBA**
Vice President, GenScript

11:40 AM – 12:05 PM
**The Pharmaceutical Industry Trends and Progress on Healthcare Reform Policies**
**Mingde Yu**
President, Chinese Pharmaceutical Enterprises Management Association; President, China Pharmaceutical Entrepreneurs Association

Lunch
*(Complimentary to All Registered Attendees and Speakers)*

12:05 – 1:05 PM
Session III: Global Success in Commercialization of Innovative Therapies

BayHelix – SAPA-GP Joint Session

1:05 – 2:35 PM

Moderators:
Sean X. Hu, PhD, MBA
Vice President and Head of Consulting, GlobalData Inc.
Patrick Deng, MBA
Director of Finance, U.S. Business Unit, IMS Health

1:05 – 1:25 PM
Strategic Decision-Making and Applications to Drug Commercialization
Sean X. Hu, PhD, MBA
Vice President and Head of Consulting, GlobalData Inc.

1:25 – 1:45 PM
Entrepreneurship & Business Management - from R&D Scientist to Start-Up
Dahai Guo, MS, MBA
Founder and CEO, PuraCap Pharmaceutical, LLC

1:45 – 2:35 PM
Panel Discussion: Global Success in Commercialization of Innovative Therapies
Moderators:
Samuel Zhang, PhD, MBA
Global Strategic Lead, Cancer Immunotherapy, Novartis Oncology
Lili Guo, PhD
Postdoctoral Researcher, University of Pennsylvania

Panelists:
Chris Chen, PhD
Senior Vice President and Chief Technology Officer for Biologics Service, Wuxi AppTec Co., Ltd.
Karen Hong, PhD
Partner, ProQuest Investments
Jay Mei, MD, PhD
Executive Director, Clinical Development, Celgene Corporation
Dongmei Wang, PhD
Senior Vice President and General Manager, CMC Services Division, Frontage Laboratories, Inc.
Samuel Zhang, PhD, MBA
Global Strategic Lead, Immuno-Oncology, Novartis

2:35 – 2:50 PM
Coffee Break
Session IV: Product Development in a Changing Regulatory and Healthcare Environment

2:50 – 4:25 PM

Moderators:
Tianjing (TJ) Hu, PhD
Senior Scientific Liaison, moksha8 Pharmaceuticals, Inc.
Allen Luo
Co-Founder, Niracle; Vice President, Technology and Business Development, AstaTech, Inc.

2:50 – 3:25 PM
Keynote Address
Perspectives on Global Pharmacovigilance
Paul Chang, MD
Chief Safety Officer and Head of Global Medical Safety, Janssen/Johnson and Johnson

3:25 – 3:50 PM
Current Trends in Biologics and Biosimilar Development and Approval
Hae-Young Ahn, PhD
Division Deputy Director, Office of Clinical Pharmacology, CDER, FDA

3:50 – 4:15 PM
Driving Innovation in China to Fulfill the Needs of All Patients
Jingsong Wang, MD
Head of China R&D; Head of Translational Medicine, Asia Pacific R&D, Sanofi

4:15 – 4:25 PM
Raffle Drawing & Closing Remarks
Aston Liu, PhD
President-Elect, SAPA-GP; Director, Biopharm CMC, GlaxoSmithKline
Hae-Young Ahn, PhD
Division Deputy Director, Office of Clinical Pharmacology, CDER, FDA

Dr. Ahn is currently the deputy director in Division of Clinical Pharmacology 3, Office of Clinical Pharmacology, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA). She joined the FDA in 1990 as a research scientist, transferred to the Office of Clinical Pharmacology as a clinical pharmacology and biopharmaceutic reviewer in 1992 and became the metabolic and endocrine clinical pharmacology team leader in 1995. In 2006 she was promoted to the deputy director in the Division of Clinical Pharmacology 3, which is responsible for the therapeutic areas of Reproductive/Urology products, Gastroenterology/Inborn Errors products and Dermatology/Dental products. As a deputy division director, she has been leading the efforts to apply quantitative methods in drug development and regulatory decision-making process. She is very active in biologics and biosimilar development and regulations. She has recently completed her detail with Office of New Drugs, Therapeutic Biologics and Biosimilar Staff. During her detail, she served as a senior advisor to the Office of New Drugs (OND) Associate Director for Therapeutic Biologics on broad policy and strategic initiatives related to follow-on products, follow-on protein products, and other related complex products. She also served as a clinical pharmacology expert resource to all OND divisions.

Dr. Ahn has been interested in international collaborations for drug development and approval. She organized joint conferences between American Society for Clinical Pharmacology and Therapeutics (ASCPT), Korean Society for Clinical Pharmacology and Therapeutics (KSCPT), and Japanese Society for Clinical Pharmacology and Therapeutics (JSCPT), and the joint conferences were held in Seoul, Korea in 2009 and in Hamamatsu, Japan in 2011. She has also organized and chaired workshops and symposia in several national conferences. She is especially interested in Korean drug development and has organized several conferences in Korea to help Korean Pharmaceutical Industry map out strategies for new drug developments. She has participated in many important CDER coordinating committees and working groups such as Complex Drug Substance Coordinating Committee, Biopharmaceutical Coordinating Committee, Non-glycosylated peptide working group, Biosimilar Implement Committee, Biologic Oversight Board, and Hepatic Impairment working group. She has received many CDER awards including Leadership Excellence Award, Excellence in Communication Award, and Special Recognition Award.

Dr. Ahn received her BS in Pharmacy from Ewha Women’s University, MS in Pharmaceutics from Seoul National University and PhD in Pharmaceutics from West Virginia University. She also received postdoctoral training in Pharmaceutics at the University of Michigan.
Eliav Barr, MD
Vice President, Head of Infectious Diseases Therapeutic Area, Global Clinical Development, Merck & Co., Inc.

In his current capacity, Dr. Barr leads the clinical research and strategic efforts to develop medicines to treat life-threatening Infectious Diseases, including Hepatitis C, HIV, CMV, and hospital-acquired bacterial and fungal infections. Infectious Disease medicines and candidate compounds in clinical trials include Merck’s HCV direct-acting antivirals MK-5172, MK-8742, and early stage compounds; ISENTRESS® (raltegravir) and MK-1439 (doravirine); MK-8228 (lettermovir); NOXAFIL® (posaconazole) and CANCIDAS® (caspofungin); and INVANZ® (ertapenem), MK-3415A (C.difficile Toxin A and B monoclonal antibodies), and MK-7655 (beta-lactamase inhibitor).

Dr. Barr joined Merck & Co., Inc. in 1995 and in 1998 became the head of the Human Papilloma Virus (HPV) vaccine clinical program. He developed the clinical/regulatory strategy for the program; designed and managed 17 clinical studies involving over 30,000 subjects worldwide; developed a program to evaluate the economic impact and long-term efficacy of the HPV vaccine, and oversaw analyses of key clinical studies. The program resulted in the first demonstration of prophylactic efficacy for a vaccine targeting HPV, and the first demonstration that prophylactic administration of a vaccine targeting HPV types 6, 11, 16, and 18 is highly effective in reducing cervical, vulvar, and vaginal cancer risk and genital wart rates caused by these types. The vaccine that was evaluated in these studies (GARDASIL®, Merck & Co., Inc.) has been licensed in over 100 countries.

After receiving his undergraduate degree from Penn State University, Dr. Barr went on to earn his medical degree from the Jefferson Medical College in 1986 (summa cum laude) and completed an Internal Medicine residency, a Cardiology Fellowship, at Johns Hopkins in 1990. He subsequently pursued post-doctoral training at the University of Michigan, and was on faculty at the University of Chicago prior to joining Merck.

Paul Chang, MD
Chief Safety Officer and Head of Global Medical Safety, Janssen/Johnson and Johnson

Dr. Chang is the Chief Safety Officer and Head of the Global Medical Safety at Janssen. As Janssen’s Chief Safety Officer, Paul has responsibility for all aspects of pharmacovigilance (PV), including medical safety assessment, PV operations, and the EU Qualified Person Pharmacovigilance (QPPV) / International PV.

Dr. Chang joined Johnson & Johnson in 2006, and has held various leadership positions in both pharmaceutical and medical device sectors including the Head of Cardiovascular Development and the Head of Internal Medicine Development at Janssen R&D, Head of Clinical Research and Project Management at Cordis Corporation, and Head of Cardiovascular & Metabolism (CV) Medical Affairs at Janssen Pharmaceuticals, Inc.
Prior to J&J, Dr. Chang held leadership positions including Vice President of CV and Immunology Global Clinical Research at Bristol-Myers Squibb; and Director of CV Clinical Research at Merck where he started his healthcare industry career.

Dr. Chang received his undergraduate degree at Columbia University and his MD degree from Yale University School of Medicine. He completed his Internal Medicine training at New York Hospital/ Cornell University Medical Center and his Cardiovascular Disease fellowship at Yale New Haven Hospital.

**Chris Chen, PhD**

Senior Vice President and Chief Technology Officer for Biologics Service, Wuxi AppTec Co., Ltd.

Dr. Chen is currently Senior Vice President and Chief Technology Officer for Biologics Service at Wuxi AppTec Co., Ltd., leading 1000-people biologics service business in China. At WuXi AppTec, he has built a world-class open-access integrated mab discovery, development and manufacturing platform to service needs from global clients. Under his leadership, WuXi AppTec became the first company in China to build capabilities to develop fully human mabs, the first company to complete IND-enabling CMC package for mabs for global registration, the first company to successfully build a cGMP biologics manufacturing facility, the first company to develop novel Antibody Drug Conjugate for global clients in China, and the first company to supply biologics drug substances and sterile drug products to US clinical trials.

Dr. Chen obtained his dual bachelor degrees of Chemical Engineering and Automation at Tsinghua University, Beijing, China and his PhD in Chemical Engineering at the University of Delaware, US. He then gained valuable experience in process development, manufacturing, technology transfer, process validation, quality, and regulatory in the US, where his previous assignments included director and manager positions of bioprocess development, technical service, and pilot plant operations at Lilly and Merck. He later joined Shanghai Celgen Biopharmaceuticals as Chief Operating Officer, successfully developed a high-titer high-quality commercial process for biosimilar Enbrel, and obtained regulatory approval for the program in China. The biosimilar Enbrel was launched in China in Sept 2011. In 2009, he co-founded Shanghai Kanda Biotechnology Co., Ltd. and served as Chief Executive Officer. In two years, Kanda became a leading mab CRO/CMO provider in China, successfully completing two Chinese IND-enabling CMC projects on behalf of clients. Dr. Chen is proficient at mab development strategy, high titer cell culture development, large-scale mammalian cell culture, and regulatory and quality of mab manufacturing. Overall, he has participated in developing 11 mab programs in US and another more than 20 in China. Dr. Chen chaired multiple conferences in biochemical engineering and mab development in US and China and is frequently invited to speak at international conferences. He is also an adjunct professor at Shanghai Jiaotong University and Military Medical Academy of Sciences.
Joon-Woon Chong
Vice President, Strategic Planning & Investment Promotion, Business Development & Commercial, Sembcorp Development

Mr. Joon-Woon Chong leads the team responsible for Sembcorp Development’s strategic planning and investment promotion, and business development for land development opportunities. Prior to joining Sembcorp in 2012, Mr. Chong spent 14 years in Singapore Economic Development Board (EDB) with 7 years based out of EDB’s United States offices. His last stint in the United States was at the San Francisco office as Regional Director of Western Americas, overseeing EDB’s multiple offices responsible for investment promotion from the western half of the United States (including Texas), western Canada and Central America. Mr. Chong was the Director of Electronics before he left the EDB. He led the team responsible for the planning, industry development and investment promotion efforts in Singapore’s electronics sector, which was the largest contributor of manufacturing investments for Singapore and accounted for more than 5% of Singapore’s GDP.

Mr. Chong graduated from the National University of Singapore with a Bachelor’s degree (with Honors) in Electronics Engineering with a specialization in semiconductors.

James Fendrick
CEO and President, Rockland Immunochemicals, Inc.

Mr. Fendrick is President and CEO of Rockland Immunochemicals, Inc. Rockland is a global biotechnology company that is renowned for its development of assays, antibodies and antibody based tools. Rockland conceives and produces monoclonal and polyclonal antibodies against targets involved in cancer and other molecular signaling pathways which are incorporated into immunoassays for detection of biomarkers for various diseases. Partnering with leading government, academic and biopharma institutions and organizations throughout North America, Europe and Asia is a cornerstone of Rockland’s success. For example, in collaboration with the National Cancer Institute’s Center for Cancer Research and the MD Anderson Cancer Center, Rockland recently released a suite of research reagents used to assess patient suitability for certain cancer therapies. Rockland’s proprietary technology and expertise spans a broad spectrum – from Lyme disease assays to VHH single-domain antibody platforms and beyond. Rockland is located in Limerick, Pennsylvania. Jim is a graduate of Gettysburg College.

Dahai Guo, MS, MBA
Founder and CEO, PuraCap Pharmaceutical, LLC

Mr. Guo is the founder & CEO of PuraCap Pharmaceutical LLC and also the founder of Enspire Group. Under Mr. Guo’s leadership, PuraCap Pharmaceutical is developing, manufacturing and marketing broad range of Branded Rx, Generic Rx and OTC pharmaceutical products in the global markets. Currently, PuraCap
has over 20 different drugs, over 100 different SKUs in US and 6 other markets. He has introduced various bio-medical products into China market.

Through his professional career, Mr. Guo has held senior positions in several multi-billion dollar global companies and also start-up companies in biotech, pharmaceutical and healthcare product industry. Mr. Guo has broad experience in sales & marketing, product development, global strategic planning and biotechnology research. He has demonstrated strong leadership in successfully marketing global healthcare brands and over 2000 different products in 90 different countries, including major retail markets like US, Canada, West Europe, Australia, China and India markets. Particularly, his strong marketing expertise has covered every sales channel in US retail (Food/Drug/Mass/e-commerce/C-stores), hospital and industrial (B-2-B) markets. His broad and hands-on experience also enabled him to build and grow another New Jersey based start-up biotech company, Cell & molecular Technology Inc., (now a division of Invitrogen) successfully 17 years ago.

Mr. Guo has MBA from Cornell University and MS of Biology from Rutgers University. He also completed distinguish Six-Sigma Black Belt training, awarded by America Society for Quality. Before he came to US, Mr. Guo conducted molecular biology research at China’s top research institute, Chinese Academy of Sciences and the Chinese International Science Center in Beijing.

Chunlin Han, PhD
Assistant Mayor of Chengdu, China

Dr. Lin received his BS degree in Signal and Information Processing from University of Electronic Science and Technology of China. He continued to pursue his PhD in Electronic Engineering and became a professor and doctoral advisor. Dr. Lin held positions with increasing responsibilities in both universities and government. He served as a member of the Party Standing Committee, and Vice President at University of Electronic Science and Technology of China. Later on, he took on multiple administrative roles in Chengdu High-Tech Zone including Vice Chair of the Party Working Committee and Director of Administration. Currently Dr. Lin is the Assistant Mayor of Chengdu.

During his tenure at University of Electronic Science and Technology of China, Dr. Lin’s research focused on radar signal processing, synthetic aperture & imaging and phased array radar technologies. He received 3 distinguished awards at the national and provincial levels, and published more than 40 articles in peer-reviewed journals.

Karen Hong, PhD
Partner, ProQuest Investments

Dr. Hong is a partner of ProQuest Investments, a US-based healthcare venture capital firm with ~$900 million under management. Dr. Hong joined ProQuest in 2001 as an Associate, became a Principal in 2004, and a Partner in 2013. Prior to joining ProQuest, Dr. Hong provided technical consultation to
the healthcare group at BancBoston Ventures and pursued academic research in molecular biology and chemistry. Most recently, she led numerous research projects in the area of mammalian cancer genetics and genomics in the laboratory of Dr. Eric Lander at the Whitehead Institute for Biomedical Research. Currently, Dr. Hong serves on the Board of Directors of Agile Therapeutics and Clarus Therapeutics and is a board observer at Mevion Medical Systems. In addition, she has represented ProQuest as an observer on the Board of Directors of BioRexis Pharmaceutical Corp. (acquired by Pfizer) and Gloucester Pharmaceuticals (acquired by Celgene), among others.

Dr. Hong received a BS in Chemistry and a BA in Molecular Biology from the University of California at Berkeley, where she graduated with honors and as a member of Phi Beta Kappa. She received a PhD in Biology from the Massachusetts Institute of Technology.

Steven R. Houser, PhD, FAHA
2016-2017 President-Elect of American Heart Association;
Senior Associate Dean of Research, Director of Cardiovascular Research, Chair of Cardiovascular Research Center, Temple University

Dr. Houser is an internationally respected cardiovascular researcher who has been a Temple faculty member for more than 30 years. His research group has helped define many fundamental features of the normal cardiac myocyte as well as identified defective molecular and cellular processes that produce abnormal cardiac myocyte function in cardiovascular disease. In 2012, this group was awarded a five-year, $11.6 million grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to develop new approaches to prevent, slow, or reverse damage to the heart after a heart attack.

Dr. Houser earned his PhD in Physiology and completed a research fellowship at TUSM. He joined the Temple faculty as an Assistant Professor of Physiology in 1979 and was named Director of the Cardiovascular Research Center in 2003, Chair of Physiology in 2006, and Senior Associate Dean for Research in 2014. He has a long association with the American Heart Association, serving as a board member, Chair of the Research Committee, President of the Southeastern Pennsylvania Affiliate, and President-Elect of American Heart Association.

Edward Hu, MS, MBA
Chief Financial Officer and Chief Investment Officer, WuXi AppTec Co., Ltd.

Mr. Edward Hu is currently Chief Financial Officer and Chief Investment Officer at WuXi AppTec. In this capacity, Mr. Hu manages WuXi’s finance, strategic investments, merger and acquisition, and new business building. In addition, he also manages WuXi’s joint ventures with MedImmune and PRA. Mr. Hu is Head of WuXi Corporate Venture Fund, spearheading the fund’s investment strategy and portfolio management. Previously, he served as WuXi’s Chief Operating Officer and Chief Financial Officer. Prior to joining WuXi, Mr. Hu was SVP and Chief Operating Officer at Tanox, responsible for operations, finance, IT, project management and strategic planning, and managed the
acquisition of Tanox by Genentech in 2007. He also held positions at Merck & Co., Inc. as a Senior Financial Analyst and later in Business and Financial Planning Manager at Biogen, Inc. (n/k/a Biogen Idec, Inc.), where he managed the business planning of Biogen's R&D and clinical development programs, and provided project planning and analysis support to key drug development project teams. Mr. Hu completed his PhD work, all but dissertation, in Biophysics and Biochemistry at Carnegie Mellon University, where he also received his MBA degree.

Sean X. Hu, PhD, MBA
Vice President and Head of Consulting, GlobalData Inc.

Dr. Hu is currently Vice President and Head of Consulting in the US for Pharmaceutical and Diagnostics at GlobalData, a global healthcare and energy business intelligence and management consulting firm. Earlier, aside from founding BioStrat Advisory LLC, for years he was a Managing Partner and Head of Bionest USA, both boutique life science strategy consulting firms.

An early participant of the Human Genome Project, Dr. Hu is now a recognized thought leader in the field of personalized medicine (PM) business strategy, advising global pharmaceutical and diagnostics companies on how best to develop and commercialize personalized medicine drug and/or molecular diagnostics, and build internal business processes and capabilities for PM products.

Dr. Hu currently serves on the Editorial Board of the peer-reviewed journal *Personalized Medicine*, in addition to several PM related industry consortia/committees. He has been a frequently invited speaker on PM at conferences and to the leadership teams of many pharma companies, along with some notable publications on this subject. As part of his extracurricular activities, he holds an Adjunct Professor position at the Chinese National Human Genome Center at Shanghai, Chinese Academy of Sciences, and Senior Advisor and Visiting Professor positions at Beijing Genomics Institute.

Dr. Hu’s earlier work experience includes serving at other consulting firms such as IMS Consulting and AT Kearney, BMS – a major pharma, Illumina – a prominent genetic analysis tool/diagnostics company, and CuraGen – a first-generation genomics biopharma.

Dr. Hu obtained his PhD in Genomics from New York University, MBA from the Wharton School of Business, University of Pennsylvania, and BS in Organic Chemistry from Beijing University.

Jeffrey Hung, PhD, MBA
Vice President, GenScript

Dr. Jeffrey Hung is Vice President of GenScript, a leading biology CRO in the world. Dr. Hung, an innovative leader in growing life science and diagnostics companies, is responsible for global strategy planning and implementation for all service lines at GenScript including gene synthesis, peptide, protein and antibody production, and genome editing.
Dr. Hung was the Chief Marketing Officer at ATCC before joining GenScript, responsible for the global sales, marketing, technology acquisitions and new product launches of the world’s largest biorepository. Prior to that role, Dr. Hung was instrumental in growing SABiosciences’ sales in 4 consecutive years which led to QIAGEN’s acquisition of the company in 2011. Dr. Hung is the author of multiple patents, peer reviewed publications and book chapters. Dr. Hung earned his PhD from Cornell University and MBA from UC Berkeley.

**Bruce Levine, PhD**  
**Director, Clinical Cell and Vaccine Production Facility, University of Pennsylvania**

Dr. Bruce Levine is the Barbara and Edward Netter Professor in Cancer Gene Therapy in Department of Pathology and Laboratory Medicine at University of Pennsylvania. He is Director of Clinical Cell and Vaccine Production Facility (CVPF) at Abramson Cancer Center and Perelman School of Medicine. He is an alumnus of University of Pennsylvania and received his PhD in Immunology and Infectious Diseases from Johns Hopkins University. The CVPF enables the translation and development of novel cell and gene therapies through validation, manufacture, and testing in single center and multi-center clinical trials in hematologic malignancies, solid tumors, HIV infection, and genetic disease. Twenty clean rooms and associated Quality Control laboratories staffed by 60 clinical laboratory scientists and regulatory professionals support the mission. Since inception, Dr. Levine and the CVPF have supported more than 30 FDA Investigational New Drug Applications at Penn and external institutions. Several CVPF trials have been first-in-human trials, including the first use of a lentiviral vector, the first infusions of zinc finger nuclease genome-modified cells, and the first use of lentivirally-modified cells to treat cancer. Dr. Levine has overseen the production, testing and release of 2200 cellular products administered to more than 800 patients in clinical trials since 1996. Through these technologies, personalized and enhanced immunity has been engineered. T lymphocytes from HIV+ subjects have been rendered resistant to HIV infection and re-infused. T lymphocytes from cancer patients have been redirected with chimeric antigen receptors to hunt and destroy their malignancies, an investigational therapy that recently received Breakthrough Designation from FDA and is currently in commercial development.

**Feng (Frank) Li, PhD**  
**President and Co-Founder, Alliance Pharma, Inc.**

Dr. Feng Li is president and one of the founders of Alliance Pharma. He obtained his PhD in Bioanalytical Chemistry jointly from Canadian Doping Control Centre and Concordia University. Subsequently, he conducted post-doctoral training in Biomedical Mass Spectrometry Facility at Mayo Clinic. Dr. Li also has a BS in Pharmacy and a MS in Medicinal Chemistry.

Professionally, Dr. Li has held responsible roles in the area of drug discovery metabolism at Phoenix International (a major CRO), in the Drug Analysis group in the Department of
Min Li, PhD  
Senior Vice President, Head of Neurosciences Therapy Area & Head of R&D China, GlaxoSmithKline

Dr. Min Li is Senior Vice President (SVP) Neurosciences, GlaxoSmithKline (GSK), overseeing neuroscience therapeutic area (NSTA). Dr. Li joined GSK in 2014 after 20 years with academic faculty at Johns Hopkins School of Medicine as professor of neuroscience. He is a graduate of Wuhan University, Johns Hopkins University, and received postdoctoral training at University of California, San Francisco. He received honors for his research, found biotech companies and consulted for various life-science, pharma and venture firms.

Rong-Cheng Li  
Partner, Beijing Kang Zhun Medical Technology Co.

Mr. Rong-Cheng Li is currently leading a clinical site management organization (SMO) that serves for multiple important clinical trials in China. Previously, he served in Guanxi CDC for over 30 years as director of multi-functional divisions. Mr. Li graduated from Guangxi Public Health School in 1976. He received epidemiological training from Nanjing Medical College in 1983 and clinical study training from Beijing Normal University in 1997.

Mr. Li played a major role in the viral hepatitis prevention and control in Guanxi, where he managed field epidemiological studies of viral hepatitis and primary liver cancer. He led the integrated hepatitis B immunization program into EPI since 1987. Mr. Li participated in vaccine clinical research since 1981.

As the Director of Center for Vaccine Clinical Research, Guangxi CDC, Mr. Li has made outstanding contribution in establishing GCP system in China for vaccine clinical trials. He and his team have carried out various clinical researches for more than 56 types of vaccines in the past 30 years, including vaccines of HBV, HAV, rabies, influenza and HPV, etc. He has made critical contribution in bringing vaccine clinical trials into a new era in China. He has been highly recognized as a leader in vaccine clinical research field by both domestic and MNC circles of vaccine industry in China.

Mr. Li has served in multiple committees of national and local government events including SFDA Drug Evaluation and Public Appraisal for Project and Award in Science and Technology. He is also a winner of 16 prizes for Science and Technique Progress from the Ministry of Health, National Government, and Public Health Bureau, Guangxi Government. Mr. Li has over 100 research publications in international and domestic journals.
Jay Mei, MD, PhD  
Executive Director, Clinical Development at Celgene Corporation

Dr. Jay Mei, executive director of clinical development at Celgene Corporation, has more than twenty years of experience in cancer research and drug development. For the past fourteen years (2001-present), he has worked on oncology drug development across all stages including drug discovery, early (phase I & II and IND submission) and late stage clinical development (phase III & IV and BLA/NDA submissions) in multi-national pharmaceutical and biotech companies, including Johnson & Johnson Pharmaceutical Division, Novartis Oncology and Celgene. He has led global clinical programs, multi-national trials and registration strategies for novel oncology agents in these organizations. Also he has been instrumental in the development and registration strategy and clinical trials in Asia-Pacific with these pharmaceutical organizations, including the clinical studies and eventual approval of Revlimid in China at Celgene. In addition, Dr. Mei has extensive experience in evaluating potential drug candidates for co-development with potential business partners.

Prior to joining the industry, Dr. Mei worked at US National Cancer Institute (NIH) for eight years on cancer research (1993-2001). He received his medical and doctoral trainings at Xiangya Medical College in China as part of an exchange program with Yale University and University of Maryland in the United States. Dr. Mei has published extensively in cancer research and drug development, and has been a co-inventor of multiple patents, and has been presenter at numerous international conferences and invited speaker in the research and medical communities. He also lectures at University of Pennsylvania, School of Medicine on clinical research, and holds an adjunct professorship at Xiangya Medical College.

Li Shi, PhD

CEO and Board Director, Shanghai Zerun Biotechnology Co., Ltd.;  
Vice President, Walvax Corporate, Walvax Co., Ltd.

Dr. Li Shi is currently leading Zerun Bio focusing on human vaccine development and commercialization. Zerun Bio is recognized by national government as a new and high tech enterprise and achieved success M&A with Walvax in 2013 as a subsidiary. Prior to joining Zerun Bio in early 2011, Dr. Shi had 25 years of experience in US in vaccine and protein product development and worked for Merck and Genzyme most of those years. He made multiple key contributions to Merck’s Gardasil® vaccine development and was involved from research stage to clinical development and commercialization. The success of Gardasil® vaccine, allowed Merck team to be awarded 2006 ACS Best Bioprocess Award, and 2007 World Pre-Galen Award (aka World Pharm Industrial Nobel Prize). The product achieved about $2 billion annual sale. Dr. Shi also served as a senior director leading three teams in Genzyme for technology development and contributed to a dozen of Gene Therapy, Protein, and Mab product development and manufacturing support activities.

Dr. Shi received his BS and MS from Peking University, PhD from University of California, and postdoctoral and MBA trainings from Scripps and Lehigh University, respectively. He has over 140
papers, patents, and presentation publications and served as a reviewer/editor for 12 international
journals and NIH fund in the field. He is a winner of W. H. Person’s Award of American Chemical
Society, and a current DIA-China advisory committee council member and a USP global biologics
expert council member. Dr. Shi is also a former president and a co-founder of SAPA-GP.

Michael Thien, ScD
Senior Vice President, Science and Technology Commercialization,
Merck & Co., Inc.

Dr. Thien has worked in new product and process development at Merck for over
25 years. After receiving his BS in Chemical Engineering from Caltech (1982), a
ScD from MIT in biochemical engineering (1988) and a post-doc at the Whitehead
Institute of Biomedical Research, Dr. Thien joined Merck Research Labs. Between 1989 and 2004, he worked in roles of increasing responsibility in new
product development in small molecules, vaccines and recombinant proteins. Dr. Thien was named a
Merck Research Labs “Divisional Scientist” in 1997 as a result of his development and plant start-up
work on CRIXIVAN, one of the first HIV protease inhibitors to be approved.

In 2005, Dr. Thien led the creation of a new late stage product development area which encompassed
development from Phase IIB through product launch, with responsibility for chemical and formulation
development and manufacturing efforts at facilities in New Jersey, Pennsylvania and Ireland. Since
2009, he added responsibilities for late stage development and technical support of in-line products for
vaccines and therapeutic proteins as well as small molecules.

Dr. Thien serves on numerous university advisory boards and on the Board of Governors for Robert
Wood Johnson Rahway Hospital of New Jersey.

Dongmei Wang, PhD
Senior Vice President and General Manager, CMC Services Division,
Frontage Laboratories Inc.

With nearly 20 years of pharmaceutical development experience, Dr. Wang’s CMC
operational oversight spans organic synthesis, formulation development, GMP
analytical testing, and GMP manufacturing of clinical trial materials. Prior to joining
Frontage in February 2007, Dr. Wang served as the director of analytical/QC at
NovaDel Pharma Inc., where she led teams in providing support for NDA product
development, clinical supplies manufacturing, CMC sections of regulatory filings, and technology
transfer to commercial manufacturing sites. Prior to NovaDel, Dr. Wang headed pharmaceutical
analysis and control group at Therics Inc. in product development for 510(k) and IND filings. Earlier in
her career, Dr. Wang was a lecturer at Graduate University of Chinese Academy of Science.

Dr. Wang earned a PhD degree in Chemistry with honors from Iowa State University, followed by
postdoctoral research at University of Chicago. She received a MS in Chemical Engineering from
Chinese Academy of Science and a BS in Chemistry from Peking University in China.
Jingsong Wang, MD  
Head of China R&D; Head of Translational Medicine, Asia Pacific R&D  
Sanofi

Dr. Jingsong Wang is currently the Head of China R&D and Head of Translational Medicine, Asia Pacific at Sanofi. Dr. Wang joined Sanofi from Bristol-Myers Squibb Co. (BMS) where he served multiple roles with increasing responsibilities including Director of Discovery Medicine & Clinical Pharmacology (DMCP), Medical Lead for Orencia product renew team, Lead for global Exploratory Development Team (EDT) and Liaison to China R&D.

Prior to BMS, Dr. Wang was at Wyeth (now part of Pfizer), where he served as Associate Director, and later as the Head for Translational Medicine and Biomarker Development in Inflammation and Rheumatologic Disease Area. Prior to that, Dr. Wang was at Brigham and Women's Hospital and Harvard Medical School, where he completed his clinical rheumatology fellowship and subsequently was an attending rheumatologist and faculty member. Dr. Wang has also completed a research fellowship at Harvard School of Public Health.

Dr. Wang has published in numerous leading scientific journals and authored a number of textbook chapters related to inflammation, autoimmune diseases and translational medicine. He is board certified in rheumatology, a diplomate of American Board of Internal Medicine.

Dr. Wang’s academic appointments include visiting professorships in China. He is an Adjunct Assistant Professor of Medicine at University of Pennsylvania, and was an attending physician at Hospital of University of Pennsylvania. He has served on the Research Grant Review Committee, National Natural Science Foundation of China (NSFC), and a Scientific Grant Reviewer, Medical Research Council (MRC), National Institute for Health Research (NIHR), National Health Service (NHS) of United Kingdom (UK) and as a member of the expert panel for Biotechnology Industry Organization (BIO) congressional staff briefing on biotechnology and autoimmune diseases, Capitol Hill, Washington DC.

Mingde Yu
President, Chinese Pharmaceutical Enterprises Management Association;  
President, China Pharmaceutical Entrepreneurs Association

Mr. Mingde Yu possesses decades of experiences in pharmaceutical manufacturing and commercialization management. Previously, he had been the Director of Chemical Industry Research Institute of Fuxin, Liaoning Province; Technology Chief and Factory Director of Fuxin Pharmaceutical Factory and Fuxin Chinese Medicine Factory; General Manager of Fuxin Pharmaceutical Corporation; Director of Fuxin Municipal Administration of Medicine; Deputy Director and Director of Provincial Administration of Medicine in Liaoning Province; Director of Finance Department and Market Circulation Department in the State Medicine Management Bureau; Director of Medicine Department and Deputy Director of the Economic Operations Bureau in State Economic and Trade Commission; Deputy Director of the Economic Operations Bureau in the National Development and Reform Commission.
Mr. Yu was invited to be a Research Scholar of the Medicine Research Center of Beijing University, Deputy Director of the Advisory Committee of Biopharmaceutical Experts sponsored by the National Development and Reform Commission, Honored Expert of the Innovative Drug Initiative Expert Committee sponsored by the Ministry of Science and Technology, Honored Expert of Medicine Circulation Industry Expert Committee sponsored by the Ministry of Commerce; Honored Expert of China’s 12th Five-Year Planning Expert Committee sponsored by the Ministry of Industry and Information Technology, Honored Expert of 9 Key Projects Assessment Committee sponsored by the Chinese Academy of Engineering. Mr. Yu is currently President of Chinese Pharmaceutical Enterprises Management Association, and President of China Pharmaceutical Entrepreneurs Association.

Samuel Zhang, PhD, MBA
Global Strategic Lead for Cancer Immunotherapy, Novartis Oncology

Dr. Samuel Zhang is currently global strategic lead for Novartis Oncology immunotherapy program, both internal development as well as in-licensing/acquisition. Prior to Novartis, Dr. Zhang led the Bristol Meyers Squibb early oncology commercial team and played a pivotal role in developing nivolumab initial registration strategy in NSCLC and RCC. The NSCLC strategy, specifically, has translated into clinical data demonstrating nivolumab overall survival benefit and unprecedented FDA speed and action to convert an accelerated approval NDA into a full approval.

Prior to BMS, Dr. Zhang spent seven years at Pfizer, rising from marketing manager/US brand lead for breast cancer hormonal therapy Aromasin to medical director/global lead for Pfizer’s then industry leading Immuno-Oncology portfolio. As US brand lead, Dr. Zhang increased product sales by fivefold over two years. Dr. Zhang started his industry career at Eli Lilly and launched ALIMTA, now backbone chemotherapy for lung cancer.

Dr. Zhang received his BS in biology from Peking University, PhD from Columbia University, and MBA from the Wharton School. Among his many volunteer services, Dr. Zhang co-founded SAPA-NE back in 1998 and served as its first General Secretary.

Shifang Zhang, PhD
Vice President, Corporate development, GENEWIZ, LLC

Dr. Shifang Zhang is currently Vice President of Corporate Development at GENEWIZ, LLC, a leading genomics service provider with its global header quarters in South Plainfield, NJ. He leads GENEWIZ’s global strategic business and technical development efforts. He joined GENEWIZ as a scientist in 2005, and subsequently held various responsibilities as Manager/Director of Molecular Biology, Director of Sales and Business Development, and Senior Director of Sales and Marketing. Prior to GENEWIZ, Dr. Zhang was cofounder and Chief Scientific Officer of BioNano, Inc., a biotech start-up in New York City devoted to developing and commercializing ultrasensitive biosensors. Dr. Zhang received his BS in Physiology and Biophysics from Peking University and his PhD in Genetics and Molecular Biology from Columbia University in the City of New York.
Zhongda Zhang, PhD
Vice President, Business Development, Pharmaron

Dr. Zhongda Zhang obtained his PhD in Organic Chemistry from University of Bern, Switzerland in 1992, followed by postdoctoral training and as a research associate at University of Pennsylvania. He received early education in Shanghai, China.

Dr. Zhang joined BIOMOL International as a Medicinal Chemist and later as head of Research & Development in ENZO. Currently, he is working for Pharmaron in Beijing. Dr. Zhang participated in SAPA’s activities since 1994 and was President of SAPA-GP in 2007-2008.

Yanping Zhao, MBA
CEO, Harbin Gloria Pharmaceuticals Co., Ltd.

Ms. Yanping Zhao joined Gloria Pharmaceuticals in January 2015 as Executive President. Before that, she had held various executive positions in the pharmaceutical industry: Division Chief at Inner Mongolia Medicines and Health Products Import and Export Corporation, Vice President at CP pharmaceutical group/CP group, COO at BMP Sunstone, Senior Advisor at Sanofi.

Ms. Zhao graduated from Shenyang Pharmaceutical University, and obtained her MBA from Dalian University of Technology.

De-Min Zhu, PhD
President and CEO, Cureport, Inc.

Dr. De-Min Zhu obtained his PhD degree in Physical Chemistry at Peking University followed by 6 years of cross disciplinary postdoctoral research at NIH and Harvard Medical School in biochemistry, biophysics, immunology, and cancer research.

Dr. Zhu then joined Merck and Pfizer where he developed his career and leadership in biopharmaceutical formulation/process for vaccines, biologics, and drug delivery. With strong support from a VC investment, Dr. Zhu founded Cureport, Inc. in 2012 and has been serving the company as President and CEO. Dr. Zhu published more than 30 peer-reviewed research papers including Zhu-Golan Method for cell receptor /ligand two dimensional interactions. He invented nPortTM nanotechnology that brought pharmaceutical a revolutionarily platform for liposome manufacturing from milligram to kilogram scales with adjustable particle size and robust reproducibility. Recently, Dr. Zhu established Cureconn Pharmaceutical at Beijing, China and has leased a 2500 m² laboratory at Zhongguancun Life Science Park to build a pilot nano medicine R&D and manufacturing center.
Sponsors
Your Single Source to Advance Your Research

Overnight Sanger DNA sequencing
Gene synthesis for complex constructs

Next generation sequencing
Full scale plasmid DNA preparations

Gain project efficiencies with timely and accurate data, flexible options, and Ph.D. technical support.

www.genewiz.com
Gene Synthesis
- DNA constructs of any length & complexity
- GenPlus™ high-throughput gene synthesis
- GenBrick™ building blocks for synthetic biology

Metabolic Pathway Assembly
- Efficient assembly of modular DNA libraries
- Optimize biosynthetic or metabolic pathways
- Build novel genetic circuits from modular parts

Protein & Pathway Optimization
- RBS design to tune translation initiation rate
- Patented OptimumGene™ codon optimization algorithm to boost protein expression

CRISPR/Cas9 Genome Editing
- gRNA in vectors from Zhang lab (Broad Institute)
- GeCKO & SAM libraries for genome-wide screens
- Custom KO/KI cell lines for therapeutic research

www.genscript.com  gene@genscript.com

Harnessing the synergies of Singapore, Chengdu and the rest of West China

The Singapore-Sichuan Hi-Tech Innovation Park (SSCIP) is the first-ever, iconic integrated urban development project jointly invested by Singapore and Sichuan (China). It is also a flagship project in the National-level New Area - “Tianfu New Area”.

SSCIP is positioned to be a modern new town to serve innovation-driven enterprises, seamlessly integrating industry, ecology and culture elements.

Tapping on the advanced industry development, master-planning & management experience in Singapore and the rich resources & strong industry capabilities in Chengdu, SSCIP enables international companies to enjoy the best of both worlds.

PARK
Location: South Park of Chengdu Hi-Tech Zone, Sichuan, China
Website: http://www.sscip.com.cn/en/

USA
Contact: +1 (626) 9919-880
Email: wilson.lee@sscip.com.cn
Got an innovative compound? Need it done fast and secure?

WuXi V-Lab
The 1st & only app for custom synthesis

For catalog chemicals, visit www.LabNetwork.com, WuXi’s chemical marketplace

Alliance Pharma
Your Trusted Partner

CORE CAPABILITIES
Alliance Pharma is a Contract Research Organization (CRO) specializing in bioanalytical services for both small and large molecules, and drug metabolism. Our extensive and diverse industrial experience includes:

- Analysis of drugs, agrochemicals and food ingredients
- Small molecule LC-MS/MS analysis
- Large molecule immunoassays
- Cell based assays
- Drug metabolism studies: drug-drug interactions (inhibition, induction), metabolic stability and protein binding

www.AlliancePharmaco.com
Shanghai Zerun Biotechnology Co. Ltd. (Zerun Bio), a Walvax member company, is an innovation driven company that develops, manufactures and commercializes novel human vaccine products. The top management team members are all from multi-national pharmaceutical companies in US, including Merck, GSK, Amgen, and Lonza etc with average of over 20 years of oversea experience. The company is highly recognized by Chinese vaccine industry and government as a new and high-tech company and one of the top companies in vaccine innovation and R&D capability. Using its proprietary Virus-like Particle (VLP) vaccine preparation technology platform, the company has developed prophylactic cervical cancer vaccine that is currently Phase 3 clinical development. In addition, multiple innovative vaccines are under preclinical development or in preparation for IND submission.

Zerun Bio achieved success M&A with Walvax in early 2013, since then the company has been on a very rapid growth path by leveraging Walvax’s rich resources in financing and government relationship, manufacturing and vaccine distribution. By integrating the strength of Zerun Bio in innovation and international collaboration with Walvax’s existing resources, Walvax has achieved the multiple cornerstones in establishing itself as an important player in the industry for developing and supplying safe, effective, and vaccines with international quality standards and lower cost to serve people in China and the developing world.

Zerun Bio highly opens to various collaborations and welcomes all talent and capable partners and individuals to join our effort for the goal of growth and developing valuable products to meet world’s medical needs.
PARTNERSHIP
IT’S WHAT TURNS SERVICES INTO SOLUTIONS

BIOANALYTICAL: 50+ LC-MS/MS for Small & Large Molecule Analysis

BIOSTATISTICS: Preclinical to Phase IV Development Support

CLINICAL: Unparalleled Access to Patients in Asia and USA; 400+ Beds

CMC: Analytical, Formulation Development, CTM Manufacturing, API Synthesis

DMPK: Rapid PK, In Vitro ADME, Metabolite Identification, Mass Balance

FRONTAGELAB.COM

For over 50 years, Rockland Immunochemicals has supported the Biomedical Research Community with a full range of the highest quality reagents and services.

Protect your experiments with Rockland antibodies.

Purifications  Cell Culture Services  Secondary Antibodies

Conjugations  Custom Antibody Production  Blocking Buffers

Primary Antibodies  Molecular Biology Services  Blood Products

800.656.7625  info@rockland-inc.com  rockland-inc.com
Pharmanon is a premier drug discovery and development service provider for the life-science industry. Founded in 2003, Pharmanon has established comprehensive and integrated R&D service platforms and employs over 2,700 scientists and staff.

Mission: To collaborate with our partners and accelerate the development of their pipelines from early discovery through clinical development.

Service Platforms:
✓ Chemistry: Discovery chemistry, medicinal chemistry and CADD
✓ in vitro and in vivo DMPK including bioanalytical sciences
✓ in vitro Biology and in vivo pharmacology (oncology, metabolic diseases, CNS, and inflammation)
✓ Safety assessment (US FDA inspected and China FDA GLP certified)
✓ CMC (process chemistry, manufacturing, GMP-API, analytical chemistry and formulation development)
✓ Small molecule-based integrated R&D services

康龙化成是全球领先的研发外包服务公司，是一家以研究为首任，以客户为中心的公司。康龙化成向全球制药公司提供一系列全方位的临床前的实验室服务。服务范围贯穿从药物发现到IND申报的全过程。康龙化成的服务旨在通过高性价比，高效率的外包服务帮助其全球客户缩短药物研发周期，降低研发成本。

Contact: Pharmanon Phone: 949-788-0586 Email: bd@pharmanon.com
Cureport, Inc. is a growing US pharmaceutical company committed to the development of nanomedicines. With a strong VC investment, Cureport has established its proprietary nanoparticle technology platform, nPort™, for drug delivery of both small molecules and biological molecules for the treatment of cancer, infection and metabolic diseases. The nPort™ technology platform enables the company to produce high quality liposomal products in a scale of multi kilograms of lipids in a single batch in a single day. The company has developed series of nano formulations to dramatically improve tumor-targeting drug delivery, enhance efficacy and reduce toxicities. Cureport develops its core technologies in-house, and contracts with CRO/CMO for regular research and GMP productions. Cureport is now building its pilot manufacture base and R&D center and in Beijing (中关村生命科学园) China.

Currently Cureport has two high level open positions: VP, Product Development (US), and CSO (China). Should you have interest in the positions please contact De-Min Zhu (508-768-5923) directly at SAPA-GP conference.

Currently the company is located at 60 Prescott St. Worcester, MA 01605. For enquiries of the company information, please email to info@cureportinc.com.
JUBILEL CONSULTING COMPANY
Delivering Optimal Solutions
We work closely with our clients and partners to apply optimal strategy and best practice to bring life-saving and health-improving products to people in need. Our services for pharmaceutical clients include:

- Regulatory affairs
- Post-approval change management
- Professional translation
- Registration documentation
- Sino-US business development and liaison
- Education and training

聚伯乐咨询有限公司
识良方者驰行千里
我们与药业客户和合作伙伴紧密合作，提供最优的策略和最佳实践，让挽救生命和增进健康的产品尽快呈给有需求的人。我们的服务项目包括：

- 医药法规事务
- 批准后产品的合规管理
- 专业翻译
- 药物注册文件
- 中美商务发展与协助
- 教育和培训

www.jubileel.com
17 years track record
250 dedicated employees
1000 bulk products for manufacture
20000 products listed (85% in stock) for R&D
We deliver the highest values to our clients, project by project

www.astatechinc.com
Keystone Business Park, 2525 Pearl Buck Road, Bristol, PA, USA, 215-785-3197

We Transfer Data to Knowledge
Formulation QbD/ PAT Reverse Engineering

www.niracle.com
SAPA-GP Has Gone Mobile

We strongly encourage you to download our mobile guide to enhance your experience at the Conference. You'll be able to plan your day with a personalized schedule, take notes, and social with other attendees.

Install APP
iPhones, iPads, iPod Touches
and Android devices

Mobile Site
Windows Phone 7
and Blackberry

http://tinyurl.com/q8attrt  http://tinyurl.com/pdklm7z
We reserved the main parking lot for regular attendees, at the crossing of Ithan Ave and Lancaster Ave, Villanova, PA (860 E Lancaster Ave, Villanova, PA). Print your parking permit and put it on the window. It’s about 700 ft from the parking lot to the Connelly Conference Center.

More information about the future events, please register at http://sapa-gp.org/sapagp/mailing-list/ or follow us on the following social websites.
大学等42所高校，在校大学生超过50万人，已形成电子信息、汽车机械、航空航天、石油化工、光电光伏、生物医药等优势产业，是全球重要的电子信息产业基地、国家新型工业化产业基地和国家新能源、新材料产业基地。

As an important economic center of western China, Chengdu hosts bases for over 30 national research institutes, including China’s Nuclear Power Research Institute, the Aircraft Design and Research Institute etc. and 42 colleges and universities, such as Sichuan University and University of Electronic Science and Technology with the number of college students in Chengdu exceeding 500,000. A number of advantageous industries have been established here in fields of electronic information, automobile machinery, aviation, petro-chemical, photovoltaic(PV) and bio-pharmacy, making Chengdu a global base for the electronic information industry and a national base for new industrialization, new energy and new materials.

成都作为西部对外开放重镇，世界500强企业已有265家落户成都。美国、德国、法国、澳大利亚等14个国家在成都设立总领馆，外国领事馆数仅次于上海和广州。先后荣获全国文明城市、国家环境保护模范城市、国家园林城市、中国软件名城、国家知识产权示范城市等称号，分别被联合国教科文组织和联合国减灾署授予“中国内陆投资环境标杆城市”，“世界美食之都”和“全球灾后重建典范城市”等称号。作为继上海、香港、北京之后中国第四个获得全球财富论坛举办权的城市。

As the gateway for West China’s opening to the world, Chengdu already hosts 265 of the Fortune 500 enterprises. Fourteen countries the U.S.A, Germany, France and Australia, have been approved to set up consulates general in Chengdu, celebrating it with the largest number of consulates general in China ranking only after Shanghai and Guangzhou. Chengdu has also been honored with the titles of National City of Culture, Model City for Environmental Protection, Garden City, City of Software and Model City for Intellectual Property. Internationally, it has been awarded the titles of Benchmark City for Investment Climate in Inland China by the World Bank, City of Gastronomy by UNESCO and Model City in Post-disaster Reconstruction and Development by the United Nations International Strategy for Disaster Reduction. Chengdu is fourth city in China, winning the right to host the Fortune Global Forum following Shanghai, Hong Kong and Beijing.

2014年，全市实现地区生产总值10056.6亿元，增长8.9%；地方公共财政收入1025.2亿元，增长16.6%；固定资产投资总额6620.4亿元，增长1.8%；社会消费品零售额4202.4亿元，增长12.0%；城镇居民人均可支配收入32665元，农民人均纯收入14478元，分别增长9.0%、11.5%。当前，成都正紧紧抓住新一轮西部大开发、全国统筹城乡综合配套改革试验区、成渝经济区和天府新区建设等重大机遇，努力肩负起建设全国“首位城市”的发展责任，认真落实“科学发展、优先发展”的发展取向，深入实施“创新驱动、转型升级”总体战略，坚持以交通先行、产业升级、立城优城、统筹城乡、全域开放“五大兴市战略”为工作抓手，朝着“打造西部经济核心增长极、建设现代化国际化大都市”的目标定位奋力前进。

In the year of 2014, the GDP of Chengdu stood at 10056.6 billion RMB, up by 8.9% from the previous year. Local public fiscal revenue was RMB 1025.2 billion, an increase by 16.6%, and fixed asset investment totaled RMB 6620.0 billion, growth by 1.8%. Total retail sales of consumer goods was RMB 4202.2 billion, up by 12.0%. Per capita disposable income of urban residents reached RMB 32665 and per capita net income for rural residents arrived at RMB 14478, an increase of 9.0% and 11.5% respectively from the previous year.

At present, Chengdu is seizing the major opportunity from China’s new round of western development with establishment of pilot areas for the National Urban and Rural Integrated Reform scheme, the Chengdu Chongqing Economic Zone and the Tianfu New Area. Taking on the responsibility of building the “Prime City” of Sichuan province, Chengdu is working toward the end of “becoming the core growth pole of western China’s economy and an modernized and international metropolis” through five city-developing strategies, namely, communication first, industrial output doubled, city construction modernized, urban-rural development integrated and opening-up fully covered. Meanwhile, Chengdu will also carry out the overall plan of “Reform & Upgrading for a leading growth in a balanced manner.”
成都是四川省省会，西部中心城市和行政副省级城市，首批中国历史文化名城，国务院确定的西南地区科技、商贸、金融中心和交通、通信枢纽，全国统筹城乡配套改革试验区。辖9区4市6县，面积1.21万平方公里。常住人口1500万。

Chengdu, capital of Sichuan Province and a sub-provincial-level city, is the central of west China. Famous for its historic and cultural profundness, Chengdu is recognized by the State Council as Southwest China’s center of science, commerce and finance and hub of telecommunication and transportation. As a pilot area for the National Urban and Rural Integrated Reform scheme, Chengdu Governs nine districts, four county-level cities and six counties, covering 12,100 km² with a resident population of 1500 million.

Situated on the west Sichuan plain with a history of 2300 years, Chengdu gained its name from the saying, “It takes one year to make a village, two years a town, and three years a city”. Rich in natural resources, Chengdu is immune from bitterly cold winters, severely hot summer, famines, floods and drought, and is therefore known as “the Land of Heavenly Bliss”. Home to several world natural and cultural heritages such as Mount Qingcheng, Dujiangyan Irrigation System and Chengdu Panda Breeding and Research Base, Chengdu boasting many national scenic sites rated 4A or above such as Wuhou Temple, Dufu’s Thatched Cottage, Jinsha Relics, Xiling Snow Mountain. Chengdu is rich in tourist attractions and therefore rated by the World Tourism Organization as China’s Best Tourist City.

(Contents continued on the inside back cover)